Related Experiment Video
Updated: Feb 14, 2026
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Remote Clinical Pharmacist Impact on Reducing Total Cost of Care in Enhancing Oncology Model-Enrolled Oncology
Daniel C Kendzierski1, Alexa J Basilio1, Andrea R Roman1
1McKesson Specialty Health, Irving, TX.
Purpose:
The Enhancing Oncology Model (EOM) is a voluntary, risk-based payment model implemented by the Centers for Medicare & Medicaid Services (CMS) to improve cancer care while reducing the total cost of care (TCOC). The US Oncology Network (The Network) comprises approximately 50% of all prescribers participating in EOM nationwide across 12 practice sites. In The Network, drug costs represented an average of 63% of a patient's TCOC. The aim of this study was to demonstrate the impact of a remote clinical pharmacist in reducing TCOC in the EOM.
Methods:
Medication initiatives were clinically evaluated and adopted at an individual practice level and included: monoclonal antibody (moAB) dose rounding, pembrolizumab dose banding, biosimilar therapeutic interchange (TIC), use of a preferred PD-1 agent, decreased up-front usage of long-acting growth factor in metastatic cancer, and use of zoledronic acid over alternatives. ClinReview pharmacists (CRPs) remotely reviewed oncology treatment orders for cost-saving opportunities and updated orders per protocols. Interventions were tracked by the CRP, and TCOC reduction was calculated using the difference between the CMS allowable for the original treatment ordered and the new order.
Results:
From July 1, 2023, to December 31, 2024, seven CRPs within five of The Network's EOM participating practices evaluated over 5,600 patients. A total of 1,180 interventions were accepted, with moAB dose rounding and TIC being top contributors. The projected sum of TCOC reduction amounted to $8,982,235, or $1,604 USD per patient. In addition to the six initiatives, the CRP contributed an additional $1,201,326 USD in medication savings associated with drug selection.
Conclusion:
CRP's medication initiatives within The Network's EOM participation reduced TCOC by nearly $9 USD million, highlighting the potential for pharmacist-driven interventions to lower costs and drive the success of value-based care models in oncology practices.
More Related Videos
06:37Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
Published on: October 20, 2010
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Related Concept Videos
01:19Impact of Groups on Groups
01:18Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
01:21Interdisciplinary Care: The Health Care Team-I
Physicians
The physician's primary responsibility is to diagnose illness and direct the medical or surgical treatment of the condition. The authority to admit patients to a healthcare agency or institution and practice care within that setting is granted to physicians by the healthcare agency or institution...
01:18Interdisciplinary Care: The Health Care Team-II
Physical Therapist
A physical therapist (PT) aims to restore function or prevent additional impairment in a patient following an injury or disease. Massage, heat, cold, water, sonar waves, exercises, and electrical stimulation are some treatments used by PTs to treat...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:30Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...